According to new research, Beyaz and other birth control pills containing drospirenone may cause heart attacks, strokes, pulmonary embolisms and even death in certain high risk users. Court records indicate that studies about drospirenone conducted before Beyaz was approved by the FDA show that drospirenone has certain effects that are very different from older contraceptives, making the drugs that contain it potentially far more dangerous.
Beyaz Update 9/11/12: A newly-released study conducted by the U.S. Food & Drug Administration (FDA) found no unexpected evidence of specific pediatric concerns regarding teen use of Bayer’s popular birth control pill Beyaz. The new research is part of the administration’s continuing effort to explore better ways of understanding the increased risk of blood clots associated with Beyaz and other drospirenone-based contraceptives. Click here to learn more.
Beyaz Update 6/26/12: A new study has found that a widely prescribed class of contraceptive products containing a synthetic hormone known as drospirenone may increase the risk for irritable bowel syndrome (IBS), a chronic condition that involves symptoms such as severe abdominal pain, discomfort, bloating, and altered bowel habits. The researchers found that women were almost twice as likely to be diagnosed with IBS after initiating a regimen of drospirenone-based birth control pills than women who took products containing levonorgestrel, a ‘third generation’ progestin found in many older types of contraceptives. Click here to learn more.
Beyaz Blood Clot Lawsuit Update 4/13/12: Pharmaceutical giant Bayer will pay at least $110 million to settle approximately 500 lawsuits over claims that its controversial line of Yasmin birth control products cause blood clots. Officials of Germany’s largest drugmaker reportedly agreed to pay an average of about $220,000 a case to resolve the complaints, people familiar with the agreements said. Click here to learn more.
Beyaz Blood Clot Update 4/10/12: Birth control products containing the synthetic hormone drospirenone have been linked to an increased risk for blood clots, according to a warning issued today by the U.S. Food & Drug Administration (FDA). In response to these findings, the FDA has required that all drospirenone-containing contraceptives carry warnings which state that several studies have found as much as a three-fold increased risk of blood clots associated with drospirenone when compared to levonorgestrel, a different hormone found in many older forms of birth control. Click here to learn more.
Beyaz Blood Clot Update 12/9/11: An independent advisory panel to the FDA has recommended that all birth control products containing the hormone drospirenone should have their labels updated to include warnings about blood clots. The panel’s recommendation was based on new data suggesting that the popular contraceptives may put women at a higher risk for dangerous blood clots than older forms of birth control. Click here to learn more.
Free Beyaz Case Evaluation: If you or a loved one has been injured by Beyaz, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.
What is Beyaz?
Manufactured and marketed by Bayer HealthCare Pharmaceuticals, Beyaz is a birth control product that contains drospirenone, ethinyl estradiol and levomefolate. Drospirenone and ethinyl estradiol prevent ovulation by inhibiting the release of an egg from the ovary, while levomefolate helps prevent a birth defect that could occur in a baby if the pregnancy occurs while taking birth control pills. Beyaz is primarily prescribed to prevent pregnancy, though it is also commonly used to treat moderate acne in women who are at least 14 years old and have started having menstrual periods.
The drospirenone contained in Beyaz is considered a newer, so-called ‘fourth generation’ progestin that is fundamentally different from earlier versions of birth control. Currently, there is insufficient data available regarding its safe use, but court records indicate that studies conducted on drospirenone has shown that its effects are far different than second generation progestins, and hence potentially more dangerous. Making matters worse, FDA officials have said they are not aware of any real benefits in the drospirenone contained in Beyaz and other similar drugs.
Side Effects of Beyaz
The drospirenone in Beyaz can increase a user’s potassium levels. This can lead to serious health problems including (but not limited to):
- Blood Clots
- Deep Vein Thrombosis (DVT)
- Venous Thromboembolism (VTE)
- Pulmonary Embolism (PE)
- Cerebrovascular Accidents (CVA)
- Heart Attack
- Myocardial Infarction
- Gallbladder Disease / Injury (cholecystitis)
- Gallbladder Removal (cholecystectomy)
Drugs Containing Drospirenone
Contraceptive medications containing drospirenone currently available on the U.S. include:
Beyaz FDA Safety Review
On May 31, 2011, the FDA announced that it was initiating a safety review of Beyaz and other contraceptives containing drospirenone after it became aware of at least two studies linking the hormone to an increased risk of blood clots. The announcement came just days after the European Medicines Agency officially determined that drospirenone-containing medications were associated with a two to three times higher risk of venous thromboembolism compared to contraceptives containing levonorgestrel. According to the FDA, the goal of the ongoing review is to fully assess the risks and benefits of drospirenone-based drugs.
Do I have a Beyaz Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Beyaz lawsuits. We are handling individual litigation nationwide and currently accepting new injury cases in all 50 states.